Metabolic Parameters Predict Survival and Toxicity in Chimeric Antigen Receptor T-cell Therapy-treated Relapsed/refractory Large B-cell Lymphoma
Overview
Authors
Affiliations
CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for patients with relapsed/refractory large B-cell lymphoma (LBCL). However, data available concerning the impact of the prognostic value of quantitative 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) parameters on the CAR T-related outcomes and toxicities are limited. Therefore, we aimed to evaluate the predictive value of pre- and post-CAR T metabolic parameters on survival and toxicities following CAR T-cell therapy. Fifty-nine patients with PET/CT scans done pre-and post-CAR T infusion were retrospectively identified and analyzed in a single institution database of LBCL patients treated with commercial CD19-targeted CAR T-cell therapy. The median follow-up was 10.7 months [interquartile range (IQR): 2.6-25.5 months]. The overall response (complete response-CR and partial response) and CR rates post-CAR T were 76% (n = 45) and 53% (n = 31), respectively. On univariate analysis, low pre-CAR T total lesion glycolysis (TLG) and metabolic tumor volume (MTV) predicted improved overall response post-CAR T (OR = 4.7, p = 0.01, OR = 9.5, p = 0.03, respectively) and CR post-CAR T (OR = 12.4, p = 0.0004, OR = 10.9, p = 0.0001, respectively). High TLG pre-CAR T was correlated with cytokine release syndrome (CRS, OR = 3.25, p = 0.04). High MTV pre-CAR T was correlated with developing immune effector cell neurotoxicity syndrome (ICANS) events (OR = 4.3, p = 0.01), and high SUV pre-CAR T was associated with grade 3-4 neurological events (OR = 12, p = 0.01). High MTV/TLG/SUVmax post-CAR T were significantly associated with inferior Overall survival (OS). On multivariate analysis, high TLG pre-CAR T (HR = 2.4, p = 0.03), age ≥60 (HR = 2.7, p = 0.03), and bulky disease (≥5 cm) at the time of apheresis (HR = 2.5, p = 0.02) were identified to be independent prognostic factors for inferior PFS. High MTV post-CAR T was identified as the most prognostic factor associated with inferior OS.
Novruzov E, Peters H, Jannusch K, Kobbe G, Dietrich S, Fischer J Eur J Radiol Open. 2025; 14():100619.
PMID: 39803388 PMC: 11719856. DOI: 10.1016/j.ejro.2024.100619.
Galli E, Guarneri A, Sora F, Viscovo M, Pansini I, Maiolo E Hematol Oncol. 2024; 43(1):e70029.
PMID: 39716447 PMC: 11666922. DOI: 10.1002/hon.70029.
Al-Ibraheem A, Abdlkadir A, Al-Adhami D, Sathekge M, Bom H, Makoseh M Front Immunol. 2024; 15:1424269.
PMID: 39286245 PMC: 11402741. DOI: 10.3389/fimmu.2024.1424269.
Sheng L, Shen R, Yan Z, Wang C, Zheng X, Zhang Y Biomark Res. 2024; 12(1):104.
PMID: 39272132 PMC: 11401356. DOI: 10.1186/s40364-024-00650-5.
Liu L, Jin F, Fan H Front Immunol. 2024; 15:1433012.
PMID: 39267739 PMC: 11390410. DOI: 10.3389/fimmu.2024.1433012.